Expanding the use of anti-PD-(L)1 agents for early-stage cancer treatment in the Czech Republic is expected to reduce events/recurrences and metastatic treatments while also extending survival, quality-of-life, and productive work years, supporting the clinical and societal value of earlier use of innovative immunotherapies.
Blezer et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: